Skip to content
Cinqair, Cinqaero(reslizumab)
Cinqaero, Cinqair (reslizumab) is an antibody pharmaceutical. Reslizumab was first approved as Cinqair on 2016-03-23. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma. The pharmaceutical is active against interleukin-5.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
immune system diseasesD007154
Trade Name
FDA
EMA
Cinqair
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Reslizumab
Tradename
Proper name
Company
Number
Date
Products
CinqairreslizumabTeva Respiratory, LLCN-761033 RX2016-03-23
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
cinqairBiologic Licensing Application2020-06-29
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
asthmaEFO_0000270D001249J45
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03D: Other systemic drugs for obstructive airway diseases in atc
— R03DX: Other systemic drugs for obstructive airway diseases in atc
— R03DX08: Reslizumab
HCPCS
Code
Description
J2786
Injection, reslizumab, 1 mg
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AsthmaD001249EFO_0000270J45—441210
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
EosinophiliaD004802HP_0001880D72.1——5——5
Eosinophilic esophagitisD057765EFO_0004232K20.0—12——2
SinusitisD012852EFO_0007486J32——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hypereosinophilic syndromeD017681EFO_1001467D72.11—1———1
LoiasisD008118B74.3—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD0105991————1
Healthy volunteers/patients—1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Nasal polypsD009298HP_0100582J33————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRESLIZUMAB
INNreslizumab
Description
Reslizumab (humanized mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID241473-69-8
RxCUI1746889
ChEMBL IDCHEMBL2107884
ChEBI ID—
PubChem CID—
DrugBankDB06602
UNII ID35A26E427H (ChemIDplus, GSRS)
Target
Agency Approved
IL5
IL5
Organism
Homo sapiens
Gene name
IL5
Gene synonyms
NCBI Gene ID
3567
Protein name
interleukin-5
Protein synonyms
B-cell differentiation factor I, colony-stimulating factor, eosinophil, Eosinophil differentiation factor, T-cell replacing factor, TRF
Uniprot ID
Q13840
Mouse ortholog
Il5 (16191)
interleukin-5 (P04401)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,589 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cinqair
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,329 adverse events reported
View more details